-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Ix0zLzFf4TXnTRop6qFm/8jHvUF1mxZodtGRyOqzUcwm5wDNMDvVg/ieeBiY7c+Q WU3Pra3iBYmHVh15VPwthQ== 0000950135-03-006139.txt : 20031223 0000950135-03-006139.hdr.sgml : 20031223 20031223154421 ACCESSION NUMBER: 0000950135-03-006139 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20031223 EFFECTIVENESS DATE: 20031223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALKERMES CLINICAL PARTNERS LP CENTRAL INDEX KEY: 0001000688 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043145043 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 000-26758 FILM NUMBER: 031071006 BUSINESS ADDRESS: STREET 1: 64 SIDNEY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174940171 15-12G 1 b48865ace15v12g.txt ALKERMES CLINICAL PARTNERS, L.P. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 Certification and Notice of Termination of Registration under Section 12(g) of the Securities Exchange Act of 1934 or Suspension of Duty to File Reports Under Sections 13 and 15(d) of the Securities Exchange Act of 1934. Commission File Number 0-26758 ALKERMES CLINICAL PARTNERS, L.P. ---------------------------------------------------------- (Exact name of registrant as specified in its charter) 88 Sidney Street Cambridge, Massachusetts 02139 (617) 494-0171 ------------------------------------ (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Class A Limited Partnership Interest --------------------------------------------------------------- (Title of each class of securities covered by this Form) None ------------------------------------ (Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains) Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports: Rule 12g-4(a)(1)(i) [X] Rule 12h-3(b)(1)(ii) [ ] Rule 12g-4(a)(1)(ii) [ ] Rule 12h-3(b)(2)(i) [ ] Rule 12g-4(a)(2)(i) [ ] Rule 12h-3(b)(2)(ii) [ ] Rule 12g-4(a)(2)(ii) [ ] Rule 15d-6 [ ] Rule 12h-3(b)(1)(i) [ ] Approximate number of holders of record as of the certification or notice date: 0 Pursuant to the requirements of the Securities Exchange Act of 1934, Alkermes Clinical Partners, L.P. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person. By: Alkermes Development Corporation II, General Partner Date: December 23, 2003 By: /s/ James M. Frates --------------------------------- James M. Frates Chief Financial Officer, Vice President Treasurer and Assistant Secretary -----END PRIVACY-ENHANCED MESSAGE-----